Enterprise Value
4.706M
Cash
80.02M
Avg Qtr Burn
-22.14M
Short % of Float
6.57%
Insider Ownership
11.43%
Institutional Own.
61.09%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Zokinvy™ (lonafarnib) Details HGPS (Hutchinson-Gilford Progeria Syndrome) or Progeria | Approved Quarterly sales | |
BLA Submission | ||
Peginterferon Lambda (Lambda) Details Infectious disease, Hepatitis D | Phase 3 Data readout | |
Lonafarnib (Ritonavir) Details Infectious disease, Liver disease, Hepatitis D | Phase 3 Data readout | |
Avexitide/GLP-1 Antagonist Details Congenital Hyperinsulinism, Metabolic disorder | Phase 3 Update | |
Peginterferon Lambda + Lonafarnib Details Hepatitis D, Infectious disease | Phase 2 Initiation |